Shilpa Medicare completes clinical studies of high concentration biosimilar Adalimumab

The drug is expected to cater to the fast growing Rheumatoid Arthritis, Plaque Psoriasis, JIA, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohns disease, HS and Uveitis markets

ProBioGen partners with Granite Bio for cell line development and GMP manufacturing services

Granite Bio's lead candidate is a novel monoclonal antibody for treatment of autoimmune and certain cancer indications. B

Athos announces research collaboration to advance precision medicine in inflammatory bowel disease

Athos will perform multi-omic molecular and genetic analyses using biopsies from archived and de-identified Lahey IBD patient samples

AMPEL BioSolutions' predicts drug options with RNA analytics & machine learning

Cosentyx receives expanded approvals in EU for use in childhood arthritic conditions

Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2

Silo Pharma expands license agreement and patent portfolio

Silo enters into commercial evaluation license agreement for next generation liposomes

GlycoEra AG appoints Tanmoy Ganguly as Chief Scientific Officer

Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics

Amytrx Therapeutic's AMTX-100 CF3 moves to phase II clinical trial for atopic dermatitis

Amarex Clinical Research guides its client to phase II of FDA trials

Medison Pharma announces multi-regional agreement with argenx to commercialize Efgartigimod

Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis

Excelra Partners with HotSpot Therapeutics to enhance allosteric drug discovery efforts

The partnership aims to enhance HotSpot's drug discovery and development efforts by incorporating GOSTAR's high-quality, annotated datasets into HotSpot's machine learning (ML) and artificial intelligence (AI) models